Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis

被引：9

作者：

Eigenmann, C

Flepp, M

Bernasconi, E

Schiffer, V

Telenti, A

Bucher, H

Wagels, T

Egger, M

Furrer, H ^{[1
]}

机构：

[1] Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland

[2] Univ Zurich Hosp, CH-8091 Zurich, Switzerland

[3] Reg Hosp Lugano, Lugano, Switzerland

[4] Univ Hosp Geneva, Geneva, Switzerland

[5] Univ Lausanne Hosp, Lausanne, Switzerland

[6] Cantonal Hosp St Gall, St Gallen, Switzerland

[7] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 36卷 / 07期

关键词：

D O I：

10.1086/368190

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We compared the incidence of bacterial pneumonia among 336 patients who discontinued trimethoprim-sulfamethoxazole (TMP-SMX) as prophylaxis against Pneumocystis carinii pneumonia (PCP) with that among 75 patients who fulfilled the criteria for discontinuation but continued receiving prophylaxis. The difference in the overall incidence rates for the 2 groups (1.2 events per 100 person-years) was not statistically significant. Discontinuation of TMP-SMX prophylaxis against PCP is not associated with a significant increase in the incidence of bacterial pneumonia among patients with a sustained CD4 cell count increase to >200 cells/muL.

引用

页码：917 / 921

页数：5

共 19 条

[1] Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: Incidence, etiologies, and clinical aspects [J].

Boschini, A ;

Smacchia, C ;

DiFine, M ;

Schiesari, A ;

Ballarini, P ;

Arletti, M ;

Gabrielli, C ;

Castellani, G ;

Geneva, R ;

Pantani, P ;

Lepri, AC ;

Rezza, G .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (01) :107-113

[2] A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. [J].

de Quiros, JCLB ;

Miro, JM ;

Pena, JM ;

Podzamczer, D ;

Alberdi, JC ;

Martínez, E ;

Cosin, J ;

Claramonte, X ;

Gonzalez, J ;

Domingo, P ;

Casado, JL ;

Ribera, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) :159-167

[3]

DEGAETANO DK, 2000, INT J ANTIMICROB AG, V16, P357

[4] Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy [J].

Furrer, H ;

Egger, M ;

Opravil, M ;

Bernasconi, E ;

Hirschel, B ;

Battegay, M ;

Telenti, A ;

Vernazza, PL ;

Rickenbach, M ;

Flepp, M ;

Malinverni, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (17) :1301-1306

[5] Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia:: prospective multicentre study [J].

Furrer, H ;

Opravil, M ;

Rossi, M ;

Bernasconi, E ;

Telenti, A ;

Bucher, H ;

Schiffer, V ;

Boggian, K ;

Rickenbach, M ;

Flepp, M ;

Egger, M .

AIDS, 2001, 15 (04) :501-507

[6] BACTERIAL PNEUMONIA IN PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS [J].

HIRSCHTICK, RE ;

GLASSROTH, J ;

JORDAN, MC ;

WILCOSKY, TC ;

WALLACE, JM ;

KVALE, PA ;

MARKOWITZ, N ;

ROSEN, MJ ;

MANGURA, BT ;

HOPEWELL, PC ;

STANSELL, J ;

TURNER, J ;

OSMOND, D ;

MERRIFIELD, C ;

MOSSAR, M ;

HIRSCHTICK, R ;

MEISELMAN, L ;

MANGHISI, KJ ;

SCHNEIDER, RF ;

REICHMAN, LB ;

MANGURA, B ;

BARNES, S ;

RICHER, B ;

AU, J ;

COULSON, A ;

CLEMENTE, V ;

SARAVOLATZ, LD ;

JOHNSON, C ;

HUITSING, J ;

KRYSTOFORSKI, A ;

POOLE, WK ;

RAO, AV ;

CLAYTON, K ;

HANSON, N ;

JORDAN, M ;

THOMPSON, J ;

MYERS, D ;

LAVANGE, L ;

KATZIN, J ;

FULKERSON, W ;

WILCOSKY, T ;

LOU, Y ;

KALICA, AR ;

WITTES, J ;

FOLLMANN, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (13) :845-851

[7] A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 X 106/I [J].

Koletar, SL ;

Heald, AE ;

Finkelstein, D ;

Hafner, R ;

Currier, JS ;

McCutchan, JA ;

Vallee, M ;

Torriani, FJ ;

Powderly, WG ;

Fass, RJ ;

Murphy, RL .

AIDS, 2001, 15 (12) :1509-1515

[8] Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era [J].

Martin, JN ;

Rose, DA ;

Hadley, WK ;

Perdreau-Remington, F ;

Lam, PK ;

Gerberding, JL .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (06) :1809-1818

[9] THE CAUSES OF DEATH IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A CLINICAL AND PATHOLOGICAL-STUDY WITH EMPHASIS ON THE ROLE OF PULMONARY-DISEASES [J].

MCKENZIE, R ;

TRAVIS, WD ;

DOLAN, SA ;

PITTALUGA, S ;

FEUERSTEIN, IM ;

SHELHAMER, J ;

YARCHOAN, R ;

MASUR, H .

MEDICINE, 1991, 70 (05) :326-343

[10] PULMONARY INFECTIOUS COMPLICATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION .2. [J].

MURRAY, JF ;

MILLS, J .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (06) :1582-1598

← 1 2 →